Search

A study led by Carlos Gonzalez and colleagues at the Center for Phage Technology at Texas A&M has led to the development of the first curative and preventive phage treatment against Xylella fastidiosa, which causes Pierce’s disease in grape

Adaptive Phage Therapeutics (APT), a clinical-stage US biotech company, just closed a $40.75 million Series B investment round led by Deerfield Management Company (and also including Mayo Clinic). This will enable APT to accelerate clinical

Technophage, a Portuguese clinical-stage biopharma company, announced today that the US FDA has granted Fast Track designation to TP-102, the company’s first phage cocktail, for the treatment of infected diabetic foot ulcers caused by three

Phico Therapeutics was awarded up to 18.2M from CARB-X to pursue phase I clinical trials using its engineered phage-based platform, SASPject™.

Felix Biotechnology, alongside researchers at Yale University (including labs of Paul Turner, Ben Chan and Jon Koff), are recruiting patients for a cystic fibrosis phage therapy clinical trial! If interested, please contact claire.cochrane@

Fixed Phage, a Glasgow-based phage biotech company commercialising phage immobilisation and stabilisation-based technology, has secured £2.4 million to scale up its fight against new microbial threats that pose risks to human health and agr

PBD Biotech has secured a £2.3m investment to take Actiphage®, a rapid, accurate phage-based bovine TB test through to validation by the World Organisation for Animal Health. This test has potential to enable farmers to effectively remove T

Liechtenstein company Lysando AG and Korean company Amicogen Inc. have forged a strategic partnership. Lysando creates Artilysin®s, which are phage lysin-based antimicrobial proteins, and partnering with Amicogen will allow them to access t

Cytophage Technologies, a Canadian phage biotech company, is about to start testing on animals a throat and nasal spray that would stop infection by COVID-19 and its variants. The idea is that the synthetic phage in their spray will stimula

PhagePro Inc., a Boston-based phage biotech company, is pleased to announce that it recently received a total of $3 million under an NIH Phase II Small Business Innovation Research (SBIR) grant and an NIH Exploratory/Developmental Research

Adaptive Phage Therapeutics (APT) announced that the FDA has accepted its Investigational New Drug (IND) application for PhageBank™ phage therapy for the treatment of Diabetic Foot Osteomyelitis (DFO). This is the third successful IND appli

Locus Biosciences announced the completion of a phase 1b trial of CRISPR-Cas3-enhanced phage targeting E. coli in urinary tract infections. The trial met all the endpoints, and represents the first randomized, placebo-controlled trial using

TechnoPhage has initiated a phase I/IIa study to test a phage treatment for diabetic foot infections. This product is the first of TechnoPhage’s pipeline to enter clinical trials, constituting an exciting milestone for the company. The resu

FDA has cleared Adaptive Phage Therapeutics to start formally investigating use of its PhageBank™ to treat prosthetic joint infections. This gives APT the green light to start a phase 1/2 clinical trial in the first half of 2021 in collabor

BiomX announced positive results of a Phase 1a phage pharmacokinetic study for inflammatory bowel disease/primary sclerosing cholangitis; they showed they could safely and successfully deliver phages to the gut. This was the first clinical

Aquaculture feed company Skretting and phage biotech company Proteon Pharmaceuticals are joining forces to trial phages to improve fish and shrimp health. Skretting will isolate strains of bacteria they'd like to target, and Proteon will de

Armata Pharmaceuticals announced a $20 Million investment to support advancement of its clinical phage development programs. Armata aims to complete a phage clinical trial (Phase 1b/2a, P. aeruginosa) and initiate three more in 2021-2022.

Paris phage biotech company Eligo Bioscience announced a new agreement worth up to $224M with GlaxoSmithKline, which is aimed at advancing Eligobiotics® for acne treatment/prevention. Eligo employs CRISPR-based phage therapeutics for microb

US biotech company Felix Biotechnology announced the initiation of its first clinical trial, CYPHY, a phase 1/2 single center trial that will test its first targeted phage therapy candidate, YPT-01, against chronic P. aeruginosa infections

Pherecydes Pharma intends to list on the Euronext Growth® Market in Paris, a European equity trading market designed for small to medium-sized firms. Pherecydes Pharma has developed a portfolio of phages against Staphylococcus aureus, Pseud